Stocks-ALLO-Allogene Therapeutics Inc.

ALLO Allogene Therapeutics Inc.

3.00 -0.16 (-5.06%)
Market ClosedDelayed Prices By NASDAQ, in USD
Trade
Stocks-ALLO-Allogene Therapeutics Inc.
ALLO Allogene Therapeutics Inc.
Trade

Allogene Therapeutics Inc. price

0% Past Week
Created with Highcharts 4.2.7 /Highstock 4.2.7
Market Cap
502.88M
Day’s Range
2.88
-
3.13
52W Range
2.88
-
11.40
Volume (3M)
1.87M
Price-Earnings Ratio
-1.22
Revenue
192K

Allogene Therapeutics Inc. Latest News

View All
JPMorgan Chase & Co. Cuts Allogene Therapeutics (NASDAQ:ALLO) Price Target to $9.00JPMorgan Chase & Co. Cuts Allogene Therapeutics (NASDAQ:ALLO) Price Target to $9.00The AM Reporter6 days agoAllogene Therapeutics (NASDAQ:ALLO) Sets New 12-Month Low at $3.36Allogene Therapeutics (NASDAQ:ALLO) Sets New 12-Month Low at $3.36The AM Reporter6 days agoAllogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T Platform at the Society for Immunotherapy of Cancer (SITC) Annual MeetingAllogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T Platform at the Society for Immunotherapy of Cancer (SITC) Annual MeetingWallstreet:Online7 days ago
Top Discussions

About Allogene Therapeutics Inc.

Allogene Therapeutics is a US-based, clinical-stage, biotechnology healthcare company focussed on developing cancer treatments. The firm’s research is based on the development of allogeneic chimeric antigen receptor T-cell therapies. Founded in 2017, Allogene Therapeutics is based in San Francisco, California and is working to provide therapeutic treatments to patients worldwide who are living with hematologic cancers and solid tumours. Allogene trades on the NASDAQ GS with the ticker ALLO. The company launched its IPO in October 2018 with what was generally considered to be one of the biggest and most lucrative public offerings in over a decade, raising $324m and resulting in a market value of over $2bn. ALLO stock rose more than 30% on its first day of public trading. The company’s successful IPO was no doubt fuelled by previous well-publicised successes. In April 2018, the firm acquired Pfizer’s allogeneic CAR T portfolio and closed its Series A round of venture capital financing, raising $300m from a premium investment consortium made up of some of the leading names in biotechnology, such as Gilead and Pfizer. Are you considering investing in this instrument? Get news and updates on price changes by adding ATT stock to your eToro watchlist now.
David D. Chang, MD, PhD
CEO
361
Employees
2017
Founded
South San Francisco, California, US
HQ
Show More
Med TechNASDAQ

Upcoming Events

1
NOV
REPORTS
Allogene Therapeutics Inc. Q3 2023 earnings report is expected to be released after market open

Analyst Forecast

Consensus
Moderate Buy
Price Target
28.00
Based on 1 analysts who covered ALLO 

ESG: A New Source of Insight

What is an ESG Score?
This number is a measure of a company’s exposure to environmental, social, and governance risks. Influencing factors include energy efficiency, safety, social policies, and more. Learn More
Powered by ESG Book
Get insight into a company's sustainability using ESG (environmental, social, and governance) scores.
0
100
55
High
Industry 
Avg. 45 
45
Environment
60
Social
53
Governance

People Also Bought